Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease.
Tuttle JB, Allais C, Allerton CMN, Anderson AS, Arcari JT, Aschenbrenner LM, Avery M, Bellenger J, Berritt S, Boras B, Boscoe BP, Buzon LM, Cardin RD, Carlo AA, Coffman KJ, Dantonio A, Di L, Eng H, Farley KA, Ferre RA, Gajiwala KS, Gibson SA, Greasley SE, Hurst BL, Kadar EP, Kalgutkar AS, Lachapelle EA, Lanyon LF, Lee J, Lee J, Lian Y, Liu W, Martínez-Alsina LA, Mason SW, Noell S, Novak J, Obach RS, Ogilvie K, O'Neil SV, Ostner G, Owen DR, Patel NC, Pettersson M, Singh RS, Rai DK, Reese MR, Sakata S, Sammons MF, Sathish JG, Sharma R, Steppan CM, Stewart A, Updyke L, Verhoest PR, Wei L, Wright SW, Yang E, Yang Q, Zhu Y.
Tuttle JB, et al. Among authors: rai dk.
J Med Chem. 2025 Apr 10;68(7):7003-7030. doi: 10.1021/acs.jmedchem.4c02561. Epub 2025 Feb 28.
J Med Chem. 2025.
PMID: 40019854